

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/561,548
Filing Date	12/20/2005
First Named Inventor	Alonso Fernandez et al.
Art Unit	<del>Not Yet Assigned</del>
Examiner Name	<del>Not Yet Assigned</del> N. Westerberg
Attorney Docket Number	4258-116

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	70
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)					
	AM	WO - 96/06822-- A1		03-07-1996	Asculai, Samuel Simon		
	AN	WO --97/04747-- A1		02-13-1997	Dunn, James M.		
	AO	WO - 89/03207-- A1		04-20-1989	Illum, Lisbeth		
	AP	WO - -01/28602-- A1		04-26-2001	Kim, Hyun, et al.		
	AQ	WO - 90/08401-- A1		08-23-1990	Mäison, Tomas		
	AR	WO - 01/01984-- A2		01-11-2001	Woiszwiło, James E.		
Examiner Signature					Date Considered		

\*EXAMINER. Include only references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard St.3.). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 18 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file, (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the information to the USPTO. Time will vary depending upon the individual case. And, amount of time to complete this form and any suggestions for reduction of time should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

# **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	4258-116
-------	---	----	---	------------------------	----------

**Complete If Known**

Application Number	10/561,548
Filing Date	12/20/2005
First Named Inventor	Alonso Fernandez et al.
Art Unit	<del>Not Yet Assigned</del>
Examiner Name	Not Yet Assigned N. Westerberg

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AS	BENEDETTI, L.M., ET AL., Microspheres of hyaluronic acid esters—Fabrication methods and in vitro hydrocortisone release , J. Control. Rel., July 1990, Page(s) 33-41, Volume 13, Number 1	
	AT	LIM, S.T., ET AL., In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin I, Int. J. Pharm., January 1, 2002, Page(s) 73-82, Volume 231, Number 1	
	AU	NISHIDA, TERUO, ET AL., Hyaluronan stimulates corneal epithelial migration , Exp. Eye Res., December 1991, Page(s) 753-758, Volume 53, Number 6	
	AV	SAND, B.B., ET AL., Sodium hyaluronate in the treatment of keratoconjunctivitis sicca, A. Ophthalmol., 1989, Page(s) 181-183, Volume 67	

Examiner Signature	/Nissa Westerberg/	Date Considered	06/17/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M.W./